OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
OptimizeRx Corporation (OPRX)
NASDAQ:AMEX Investor Relations:
optimizerx.com/investors
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Fourth Quarter Revenue: $32.2 million. Full Year Revenue: $109.4 million. Fourth Quarter Adjusted EBITA: $12 million. Full Year Adjusted EBITA: $24.3 million. Fourth Quarter Gross Margin: Full Year Free Cash Flow: $18.7 million. Fourth Quarter Net Income: $5 million or $0.26 per diluted share. Fourth Quarter Non-GAAP Net Income: $9.9 million or $0.51 per diluted share. Cash and Short-term Investments: $23.4 million as of December 30, 2025. Debt Balance: $26.3 million as of December 30, 2025. 2026 Revenue Guidance: $109 million to $114 million. 2026 Adjusted EBITA Guidance: $21 million to $25 million. Revenue Retention Rate: Average Revenue per TOP20 Pharmaceutical Manufacturer: $2.8 million. Revenue per FTE: Warning! GuruFocus has detected 4 Warning Sign with OPRX. Is OPRX fairly valued? Test your thesis with our free DCF calculator. Release Date: March 05, 2026 For the complete transcript of the earnings
Show less
Read more
Impact Snapshot
Event Time:
OPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPRX alerts
High impacting OptimizeRx Corporation news events
Weekly update
A roundup of the hottest topics
OPRX
News
- OptimizeRx (OPRX) had its price target lowered by Lake Street Capital from $24.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- OptimizeRx (OPRX) had its price target lowered by Roth Mkm from $32.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- OptimizeRx (OPRX) had its "buy" rating reaffirmed by B. Riley Financial, Inc.. They now have a $11.00 price target on the stock, down from $28.00.MarketBeat
- OptimizeRx (OPRX) had its price target lowered by Stephens from $17.00 to $10.00. They now have an "equal weight" rating on the stock.MarketBeat
- OptimizeRx (OPRX) was given a new $17.00 price target by Stifel Nicolaus.MarketBeat
OPRX
Earnings
- 3/5/26 - Beat
OPRX
Sec Filings
- 3/5/26 - Form 8-K
- 2/13/26 - Form 4
- 12/23/25 - Form 4/A
- OPRX's page on the SEC website